Summit Therapeutics (SUMM)
16/11/2017 - 07:00 RNS
09/11/2017 - 13:42 StockMarketWire
Summit Therapeutics has confirmed that new preclinical data shows a positive effect of utrophin modulation on improvin...
Summit Highlights Utrophin Modulation as a Potential Universal Treatment Option in DMD at Action Duchenne
09/11/2017 - 12:00 RNS
A statement giving an update on research (e.g. clinical trials)
06/11/2017 - 13:41 StockMarketWire
Summit Therapeutics confirmed that the Company has entered into an equity and revenue sharing agreement with the W...
Join interactive investor
- £22.50 fixed quarterly charge includes £22.50 in trading credits
- £10 per trade or £6 for frequent traders
- No % platform fees
- £1 per trade for regular investment or dividend reinvestment